Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ: CYTK )

46.16 +4.54 (+10.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024
CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
(CYTK) - Analyzing Cytokinetics's Short Interest
Via Benzinga
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Incredible Growth Stocks to Buy Right Now
These two biotech stocks could be big winners in the years ahead. 
Via The Motley Fool
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Via Benzinga
Unpacking the Latest Options Trading Trends in Cytokinetics
Via Benzinga
Here's How Much $1000 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Via Benzinga
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
Masters In Trading - Saturday, March 16
In this snippet from Friday's trading session, I review my various trades from the past week. 
Via Talk Markets
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Super Micro, Deckers To Join S&P 500 Index
They'll replace Whirlpool and Zions Bancorp on March 18. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Here's How Much $1000 Invested In Cytokinetics 5 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $100 Invested In Cytokinetics 5 Years Ago Would Be Worth Today
Via Benzinga
Overbought, Overextended - What's The Buzz In S&P 500 Now?
Here are the red flags you need to be aware of in this current market and the directional bias for the long-term, swing and immediate term. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease. 
Via Investor's Business Daily
Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Monday. Shares of Banco Santander, S.A. (NYSE: SAN) shares fell sharply during today’s pre-market trading. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound. 
Via InvestorPlace
Biotech Playbook: Small Caps Show Momentum Peaking During
The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... 
Via Benzinga
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones index falling over 150 points on Thursday. Shares of Aspen Aerogels, Inc. (NYSE: ASPN) fell sharply during Thursday’s session after the company issued a... 
Via Benzinga
Topics Stocks
Exposures US Equities
Bullish Continuation In '24? 3 Market Areas To Watch
This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
Via Talk Markets
What's Been Happening With Cytokinetics Stock?
Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.